GLOBAL LIVER INSTITUTE
As the world continues to gain a better understanding of COVID-19 and ever present and new variants, Global Liver Institute wants to ensure that we are here to continue to guide, educate, and support the liver cancer community and other immunocompromised patients…
As we enter a third calendar year marked by COVID-19, the Omicron variant has caused pandemic peaks in cases and hospitalizations. However, we also have a greater understanding of the disease–and more tools at hand–than ever before. You may feel inundated with updated guidelines…
The Global Liver Institute (GLI) has been consistent, since March 2020, in advocating for the prioritization of liver patients, cancer patients, transplant recipients, and those with compromised immune systems in research, healthcare, and vaccine allocation strategies. We have taken data…
(Washington, D.C., Friday, August 13, 2021)—Global Liver Institute (GLI) CEO and President Donna R. Cryer, JD, today applauded dual actions from U.S. government health agencies: U.S. Food and Drug Administration approval of an additional COVID-19 mRNA vaccine dose for organ…
As COVID-19 vaccines roll out, more and more schools and workplaces are inching toward fully reopening for in-person work or instruction. While the mental health challenges of being disconnected from other people and our normal routines have been driving factors to the push for reopening…
As more Americans have received at least one dose of a COVID-19 vaccine than have tested positive for the virus1, we are seeing some hope for defeating the pandemic with science. While different states are announcing their plans for vaccine distribution, you might be wondering how this…
Here at GLI, we understand the vital role that caregivers/carepartners play in the lives of liver patients. Caregivers are more important than ever during the COVID-19 pandemic, but it has brought new challenges when navigating the medical system. This GLI update, and our recent GLI LIVE episode on “Caregiving During COVID” with Dr. Donnica Moore, explores…
Although all humans appear susceptible to infection by the COVID-19 virus, some communities and some racial and ethnic groups are infected, experience greater illness, and are hospitalized at rates higher than other groups, and are more likely to die. The disparities in infection, illness, and death are not just based on race or ethnicity, but may also be related…
Throughout these past many months, we have all been working to stay safe, healthy, and up to date on all things COVID-19 related. The GLI team has been actively engaging with fellow advocacy groups, healthcare professionals, and liver patients to learn and understand COVID-19 and how it impacts our health and our daily lives. We have been staying connected…
The effects of the novel coronavirus pandemic on liver patients’ ability to access non-COVID-19 related care have been broad, and pervasive. The guidance for initiation of treatment and management for patients with viral hepatitis, transplant, and cancer have been in flux during…
We recently recognized National Doctor’s Day in the US and joined people from around the world to applaud and celebrate all medical professionals working in the trenches and on the frontlines of care, fighting the coronavirus pandemic without rest or pause. Tens of thousands…
Either by the immunosuppressive nature of our conditions or as an effect of the medications we are taking, liver patients should be considered vulnerable and at high-risk for contracting a COVID-19 infection. Patients should stay home and should not Travel. The evidence continues…
